Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy Subjects

Sponsor
Eisai Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT01396590
Collaborator
(none)
54
1
2
3
18.3

Study Details

Study Description

Brief Summary

The purpose of this study is to determine that six 2-mg tablets of perampanel are bioequivalent to one 12-mg tablet of perampanel.

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
54 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Randomized, Open-label, Crossover Study to Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy Subjects
Study Start Date :
Dec 1, 2010
Actual Primary Completion Date :
Mar 1, 2011
Actual Study Completion Date :
Mar 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: 6 x 2 mg perampanel

Drug: Perampanel
6 x 2 mg perampanel once per day

Active Comparator: 12 mg Perampanel

Drug: Perampanel
12 mg perampanel once per day

Outcome Measures

Primary Outcome Measures

  1. Cmax of 6 x 2-mg perampanel tablets (reference) compared to that of the 12-mg perampanel tablet (test) [8 days]

  2. AUC(0-t) of 6 x 2-mg perampanel tablets (reference) compared to that of the 12-mg perampanel tablet (test) [8 days]

  3. AUC(0-inf) of 6 x 2-mg perampanel tablets (ref) compared to that of the 12-mg perampanel tablet (test) [8 days]

Secondary Outcome Measures

  1. The incidence of AEs [8 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion:
  1. Healthy male or female subjects, age 18 to 55 years old, inclusive, at Screening

  2. Body mass index (BMI) of 18 to 32 kg/m^2, inclusive, at Screening

Exclusion:
  1. Subjects who are taking any prescribed or over-the-counter drug or herbal remedies in the 2 weeks prior to Screening (unless the OTC drug has a long halflife [i.e., 5 x 1/2 greater than 2 weeks]) with the exception of acetaminophen (up to 4 g/day), which is allowed up to 12 hours prior to dosing

  2. Subjects who have taken St John's Wort or other dietary aids known to induce CYP3A4 within 4 weeks prior to dosing

  3. Subjects who have taken any inhibitor of CYP450 within 2 weeks prior to the first dosing (e.g., grapefruit, grapefruit juice, grapefruit-containing beverages, apple or Seville orange products)

  4. Subjects who have received any experimental drug within the 12 weeks leading up to the start of study drug treatment or who are currently enrolled in another clinical trial

  5. Subjects with a known or suspected history of alcohol abuse within the 6 months prior to Screening or who have a positive urine drug test or breath alcohol test at Screening or Baseline, or who are unwilling to abstain from consumption of alcohol throughout the periods of in-patient confinement

  6. Subjects who consume more than 5 caffeinated beverages per day (e.g., 5 cups of tea, coffee or cans of cola) or who are unwilling to abstain from consumption of caffeine-containing food and beverages throughout the periods of in-patient confinement

  7. Subjects who smoke more than 5 cigarettes (or equivalent amount of tobacco) per day or who are unwilling to abstain from the use of nicotine-containing products throughout the period of in-patient confinement

  8. Subjects who have a history of drug abuse or dependence or have a positive result from a urine drug screening test

  9. Women of child-bearing potential who do not agree to use 2 methods of adequate contraception (e.g., intrauterine device, barrier methods with spermicide) throughout the study and for 30 days after study drug administration

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fargo North Dakota United States

Sponsors and Collaborators

  • Eisai Inc.

Investigators

  • Principal Investigator: Robert Cooper, Eisai Medical Services

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT01396590
Other Study ID Numbers:
  • E2007-A001-040
First Posted:
Jul 19, 2011
Last Update Posted:
May 4, 2012
Last Verified:
Apr 1, 2012
Keywords provided by Eisai Inc.

Study Results

No Results Posted as of May 4, 2012